Antibody Formation after Vaccination with Different mRNA Vaccines and after COVID-19 Infection

A research team at the Paul-Ehrlich-Institut has compared the antibodies formed after vaccination with the COVID-19 Comirnaty vaccine from BioNTech/Pfizer – currently the most widely used in Germany – with those formed after vaccination with vaccine candidate CVnCoV (CureVac), which has been withdrawn from the authorisation process, and after COVID-19 infection. Specific antibody levels, neutralisation capacity, and binding ability of the antibodies vary considerably from person to person following vaccination with Comirnaty and after COVID-19 infection on the one hand, and following vaccination with CVnCoV on the other hand, which may help to explain the differing efficacy.

Quelle: IDW Informationsdienst Wissenschaft